HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First UK CBD Novel Food Authorizations Not Expected Until 2024 At The Earliest

Executive Summary

Summer 2024 is the earliest that the UK Food Standards Agency expects CBD applications to be fully authorized, according to its most recent board meeting. However, even this belated deadline could slip if the Home Office complicates matters or if the FSA is flooded with other regulated product applications. Meanwhile, the official CBD list has swelled to over 12,000 products, with thousands now validated and a few “removed” by mistake. 

You may also be interested in...



UK Proposes Accelerating Authorizations Of Novel Supplements Like CBD

UK Food Standards Agency proposes shaving a minimum of three months off novel food authorization procedure as part of wider plans to shake-up the process for products like CBD supplements.

Private Equity Firm Acquires Irish Generics Player Chanelle

The private equity firm Exponent has acquired Ireland’s biggest generics producer, Chanelle Pharma, following past media reports of the pharma’s nearing sale, which estimated the price north of €300m.

FSA Review Could Shake Up UK's Approach To Novel Foods

The Food Standards Agency is critically evaluating the UK's novel foods authorization process to ensure it strikes the optimal balance between promoting innovation and protecting consumers. Assessing regulatory approaches to novel foods outside the EU is central to the review, which has been prompted by Brexit.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel